AI-driven protein-based drug developer Cyrus Biotechnology is spinning out a biotechnology firm, Levitate Bio, transitioning its software, services, and IT operations. This development is expected to expand the Cyrus platform's reach across biopharma.
Following the transition, Levitate Bio will be wholly owned by the Rosetta Commons Foundation (RCF) and led by Cyrus’ former director of engineering. Cyrus continues to benefit from the platform, and Levitate Bio will work to build a broader market by attracting new customers and expanding the range of available services.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.